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The Langendorff isolated rat heart preparation was used to determine the effect of oxypurinol, a 
xanthine oxidase inhibitor, and deferoxamine, an iron binding agent, on the extent of myocardial 
reperfusion injury after 60 minutes of ischaemia. Thirty rats were divided into three groups of 
10. and an isolated heart preparation made from each rat. The isolated hearts were perfused for 
15 minutes with a modified Krebs-Henseleit perfusate solution to permit stabilisation of the 
preparation. Each heart was then subjected to 60 minutes of total ischaemia at 37°C followed by 
60 minutes of reperfusion with either saline treated perfusate, oxypurinol treated perfusate (1.3 
mmol/litre), or deferoxamine treated perfusate (0.61 mmol/litre). Reperfusion injury was 
assessed by the total amount of creatine phosphokinase released into the perfusate, by changes in 
myocardial vascular resistance, and by morphological examination. The saline treated group 
released significantly more creatine phosphokinase into the perfusate than either the oxypurinol 
treated group (p<0.05) or the deferoxamine treated group (p < 0.05). The mean vascular 
resistance increased for all groups during the 60 minutes of reperfusion compared with that just 
before ischaemia but was significantly greater in the saline treated group than in the drug treated 
groups (p < 0.01). Ultrastructural examination of a randomly selected heart from each group after 
60 minutes of reperfusion showed pronounced attenuation of mitochondria1 and endoplasmic 
reticulum swelling, increased maintenance of membrane integrity, and diminished separation of 
myofilaments in the oxypurinol treated and deferoxamine treated hearts. The mean cross 
sectional area of mitochondria after 60 minutes of reperfusion was significantly greater in the 
saline treated group than in the drug treated groups. Thus both oxypurinol and deferoxamine, 
given after 60 minutes of ischaemia at the onset of reperfusion, can protect the isolated rat heart 
from reperfusion injury, 
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The prompt return of circulation to ischaemic myocardium is necessary to sustain tissue viability. 
Reperfusion supplies the tissue with molecular oxygen and other essential energy forming 
substrates. However, the life sustaining reperfusion may also cause progressive tissue damage by 
initiating deleterious chemical reactions involving partially reduced forms of oxygen--a 
phenomenon referred to as reperfusion injury or the oxygen paradox.
1-5
 Cytotoxic oxygen 
metabolites such as superoxide, hydrogen peroxide, and the hydroxyl radical have been 
implicated as the mediators of such reperfusion injury.
1, 3, 6, 7
  These partially reduced oxygen 
species may be generated from a series of reactions that begin with the accumulation of xanthine, 
hypoxanthine, NAD(P)H, and low molecular weight free iron during of hypoxia.
1, 8
  Reperfusion 
of the affected tissue then supplies oxygen to drive these reactions.
1-3
  Xanthine oxidase, an 
enzyme present in virtually every tissue of the body, may be very important in the generation of 
superoxide, and iron may catalyse the formation of hydroxyl radical during reperfusion of 
transiently ischaemic tissues. 
 
Support for this mechanism of injury has accumulated in recent years through reports of 
protection against reperfusion injury with compounds that scavenge free radicals or inhibit 
various steps in their formation. Superoxide dismutase plus catalase protected the in vivo dog 
heart,
9, 10
 and the isolated rabbit heart,
11
 from reperfusion injury when administered before the 
period of reperfusion. Allopurinol, a xanthine oxidase inhibitor, plus superoxide dismutase 
protected the in situ dog heart from reperfusion injury after 90 minutes of regional ischaemia.
12
 
Unlike most clinical situations, however, these studies tested the effects of drugs administered 
before the period of ischaemia. Practical prevention of reperfusion injury in the setting of 
coronary thrombolysis, for example, would require that the protective drug be given after the 
onset of ischaemia, just before reperfusion. It is therefore important to determine if treatment 
administered after the ischaemic injury, at the onset of reperfusion, can provide the same 
protection that pretreatment provides. 
 
Previous studies in our laboratory have provided support for the ability of drugs to reduce 
reperfusion injury when given after the period of ischaemia, at the onset of reperfusion. 
Deferoxamine, an iron chelating agent, or allopurinol, a xanthine oxidase inhibitor, increased 
survival in a rat model of cardiorespiratory arrest and resuscitation when administered after the 
return of spontaneous circulation.
13, 14
  The present study was conducted to determine if chelation 
of free iron by deferoxamine, or inhibition of superoxide production by the xanthine oxidase 
inhibitor, oxypurinol, are effective means of protecting against reperfusion injury when 
administered after ischaemia, at the onset of reperfusion. 
 
Materials and methods 
 
ISOLATED HEART MODEL 
 
A Langendorff isolated rat heart preparation was used in this study.
15
  After anaesthesia with 
ketamine hydrochloride (90 mg/kg, ip), the heart and proximal aorta were excised from each rat, 
quickly weighed, and immersed in ice cold perfusion solution. Myocardial contractions ceased 
within 5 sec. The aortic root was then cannulated and perfusion begun. Coronary artery perfusate 
entered the aortic root and coronary arteries from a reservoir set at 100 cm above the cannula to 
provide a perfusion pressure of 76 mmHg. A cardiac electrogram was recorded by connecting a 
3 
 
cardiac preamplifier to a pin electrode at the apex of the heart and to the metal perfusion cannula 
and displayed on a Physiograph recorder. The perfusion medium was a modified Krebs-
Henseleit solution consisting of (mmol/litre): KCl 4.0, NaCl 100, CaC12 2.0, NaH2PO4 2.0, and 
lactate 30, warmed to 37 °C. The perfusate was adjusted to a pH of 7.4 with NaOH, and bubbled 
with 100% O2 after the heart had been mounted on the perfusion apparatus, a stab incision was 
made in the left ventricular apex and a 1.0 cm long polyethylene drain inserted to allow exit of 




Thirty male Wistar rats, each weighing between 350-450 g, were divided into three groups of 10 
each: saline treated, deferoxamine treated, and oxypurinol treated. The isolated heart preparation 
from each rat was allowed a 15 min period of stabilisation, followed by 60 min of total 
ischaemia, during which time the heart was immersed in a nitrogen bubbled bath of Krebs-
Henseleit solution at 37 °C to minimise oxygen reactions at the epicardial surface. The heart was 
then reperfused for 60 min with oxygenated perfusate. The deferoxamine treated hearts were 
reperfused with perfusate that contained 0.61 mmol/litre deferoxamine mesylate. The oxypurinol 
treated hearts were reperfused with perfusate that contained 1.3 mmol/litre oxypurinol. The 
saline treated hearts were reperfused with Krebs-Henseleit solution that contained a volume of 
isotonic saline equivalent to the volume of drug solution added in the other groups (2 ml). 
 
ASSESSMENT OF INJURY 
 
Myocardial injury was evaluated by three criteria: changes in coronary vascular resistance, 
changes in creatine phosphokinase release into the effluent, and changes in morphology. The rate 
of perfusate flow through the myocardium was measured by timed collection, and aliquots of 
effluent were reserved for creatine phosphokinase determination immediately after cannulation, 
at 5 min and 1 min before ischaemia, at 1 min and 5 min after the beginning of reperfusion, and 
at 10 min intervals thereafter. 
 
The myocardial vascular resistance was calculated by dividing the pressure (kPa where 1 kPa = 
7.5 mmHg) by the flow rate (litre/min) and was expressed as kPa-min/litre. The creatine 
phosphokinase assay was based on a modification of the method of Rosalkii
6
 and was expressed 
as Sigma units (SU) released per minute per gram of tissue. One SU of creatine phosphokinase 
will phosphorylate one nanomole of creatine per minute at 25 °C under the conditions of the test. 
Triplicate control assays were performed with oxypurinol, deferoxamine, creatine phosphokinase 
standard, and experimental samples to ensure that these drugs, or the Krebs-Henseleit solution 
itself, did not interfere with creatine phosphokinase activity. There was less than 3% variation in 
measured creatine phosphokinase activity in any of these quality control tests. The creatine 
phosphokinase assays were all performed within 2 hours of collection. 
 
The morphological evaluation of the myocardium used specimens collected at the end of 
reperfusion (t =+60 min). The heart was fixed by perfusion with Trump’s solution (a mixture of 
2% glutaraldehyde and 10% buffered formalin), followed by collection of standardised sections 
from the mid-left ventricular free wall for ultrastructural examination. These sections for electron 
microscopy were then stored in cold Trump’s solution. Standard procedures were used for the 
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preparation of this tissue for transmission electron microscopy. Morphometric studies were done 
to measure the mitochondrial cross sectional area, and a qualitative assessment was made of 
other morphological features such as membrane integrity, intracellular oedema and myofibrillar 
architecture. The morphometric studies used the Video Image Analysis System (WAS; SciCom 
Computer Consultants Co, Irvine, CA, USA) and a 10 x 10 cm grid, which was placed over each 
of five randomly selected photomicrographs (X 8250 magnification) of tissue that was taken 
from the mid-left ventricular free wall of each heart. Systematic measurement of the cross 
sectional area of the mitochondria closest to 25 preselected points on each grid was done. 
Therefore, a total of 125 mitochondria from each heart were evaluated. A mean ( SEM) value 
was then calculated for each group for subsequent statistical comparison, Serial transverse 
sections of the remaining heart tissue from each preparation were fixed in 10% formalin then 
later embedded in paraffin, sectioned, and stained with haematoxylin and eosin for light 
microscopical examination. 
 
Unlike the serial determinations of creatine phosphokinase release and vascular resistance, the 
morphological evaluation of the hearts could be done only at a single point in time. Therefore, 
four separate groups of three hearts each were evaluated as controls against which the three 
treated groups could be compared. Control group 1 was examined after the 15 min stabilisation 
period with no subsequent ischaemia or reperfusion. Control group 2 was allowed a 15 min 
period of stabilisation then subjected to 60 min of ischaemia without any reperfusion before 
fixation. Control group 3 was subjected to 60 min of ischaemia followed by 60 min of 
reperfusion without any treatment. Control group 4 was allowed to beat continuously for the 135 




The mean values for the change in myocardial vascular resistance, the creatine phosphokinase 
measurements, and the mitochondrial cross sectional area were determined for each group of rats 
at each collection time. Student’s t test was used (two tailed analysis) to test the null hypothesis 
that there was no difference for these values between each drug treated group and the saline 
treated group. In addition, an analysis of variance (ANOVA)
17
 was performed for the mean 
mitochondrial cross sectional area for the three treated groups and the four control groups. A p 






The mean vascular resistance increased for all groups during the 60 min of reperfusion, 
compared with that just before ischaemia (t = -1 min), but the increase was significantly greater 
in the saline treated group than in the drug treated groups. The vascular resistance (kPa-min/litre) 
increased by 2870 ( 273) for the saline treated group, by 722 ( 282) for the deferoxamine 
treated group (t = 3.50, df = 18, p < 0.01) , compared with the saline treated group), and by 549  
( 141) for the oxypurinol treated group (t = 3.94, df = 18, p < 0.01, compared with the saline 
treated group). There was no significant difference between the deferoxamine treated and the 
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oxypurinol treated groups. The sequential vascular resistance values, determined at each 




FIG 1 (a) Sequential mean( SEM) myocardial vascular resistance and (b) sequential mean ( SEM) 
values for creatine phosphokinase for the three groups during the period of reperfusion. For clarify, 




CREATINE PHOSPHOKINASE RELEASE 
 
The mean total creatine phosphokinase released during the entire reperfusion period was 
significantly greater for the saline treated group than for either of the drug treated groups. The 
total creatine phosphokinase released (SU per gram per 60 min of reperfusion) was 1137 ( 311) 
for the saline treated group, 452 ( 209) for the deferoxamine treated group (t = 4.10, df = 18,  
p < 0.01, compared with the saline treated group), and 231 ( 200) for the oxypurinol treated 
group (t = 4.21, df = 18, p < 0.01, compared with the saline treated group). There was no 
significant difference between the drug treated groups. The sequential creatine phosphokinase 
release (namely, creatine phosphokinase released at each collection time, as opposed to total 




There were no observable differences in the light microscopical appearance of the three 
treatment groups or the four control groups. All hearts showed an occasional indistinct loss of 
cross striations but no definitive evidence of myodegeneration. However, the ultrastructural 
features showed pronounced alterations. The mitochondrial cross sectional area of all groups is 
given in the table. The values for control group 1 (pre-ischaemia), control group 2 (ischaemia 
and no reperfusion), and control group 4 (no ischaemia and continuous perfusion) were 
significantly less than all other groups. However, both the deferoxamine treated and the 
oxypurinol treated groups had significantly smaller mitochondrial cross sectional area than either 
control group 3 (ischaemia and reperfusion) or the saline treated group. All groups that were 
subjected to ischaemia showed increased interfibrillar space suggestive of intracellular oedema. 
Control group 3 (ischaemia and reperfusion) and the saline treated group also showed 
pronounced distortion of mitochondria1 cristae, myofibrillar disruption, and sarcoplasmic 
reticulum membrane damage (Figure 2). Both of the drug treated groups showed moderate 
amounts of intracellular oedema but no evidence of ruptured membranes. 
 










This study showed that deferoxamine and oxypurinol can partially protect the isolated rat heart 
from reperfusion injury when administered after 60 min of warm ischaemia at the beginning of 
recirculation. Myocardial protection was evident by diminished creatine phosphokinase release, 
smaller increases in myocardial vascular resistance, and less severe morphological alterations in 
the deferoxamine and oxypurinol treated groups compared with the saline treated or the non-
treated control groups. These findings lend additional support for the concept of xanthine oxidase 
mediated, iron catalysed free radical formation during reperfusion injury. 
 
Reperfusion injury appears to be dependent on several events, some of which begin during the 
period of ischaemia.
18
  These events can be thought of as occurring in three phases. The first 
phase consists of the period of anoxia in which the tissue is depleted of its natural defence 
mechanisms against free radical injury and during which endogenous xanthine dehydrogenase is 
converted to the potential superoxide producing enzyme xanthine oxidase.
1, 19
  Reducing 
equivalents and other substrates for superoxide radical generation such as hypoxanthine and 




The second phase begins with the restoration of circulation to ischaemic tissue and is 
characterised by the rapid and overwhelming, but still reversible, generation of superoxide and 
other free radicals. These free radicals accumulate in an environment now depleted of its natural 
defence mechanism
4, 6
  Iron may play a key role at this stage of injury by converting the 
relatively innocuous superoxide radicals into the strongly oxidising hydroxyl radical via the 




The third phase is irreversible and begins with the initiation and propagation of cell protein and 
membrane lipid peroxidation by the free radical species (especially the hydroxyl radical) 
generated during phase two. This phase of injury is characterised by pronounced morphological 
and functional changes of the tissue. The present study was based on this stepwise hypothesis for 
the pathogenesis of reperfusion injury and the known action of oxypurinol (inhibition of the 
xanthine oxidase produced in phase one) and deferoxamine (inhibition of iron catalysed reactions 
in phase two). 
 
Allopurinol, a less water soluble inhibitor of xanthine oxidase than oxypurinol, has been shown 











 and kidney transplantation.
26, 27 
However, except for the cardiorespiratory arrest studies, the allopurinol was administered before 
the ischaemic insult and was not analogous to most clinical situations of ischaemia and 
reperfusion. 
 
Deferoxamine has been shown to increase the survival of rats after cardiorespiratory arrest and 
resuscitaton when given after the return of spontaneous circulation . In addition, Myers and 
colleagues have shown that deferoxamine, given during the hypoxic period, could decrease 
creatine phosphokinase release from isolated rabbit hearts after 60 min of warm ischaemia.
28




The results of the present study add additional support for the therapeutic effectiveness of a 
xanthine oxidase inhibitor and an iron chelator in reperfusion injury and support the theory of 
xanthine oxidase mediated, iron catalysed free radical production in reperfusion injury. It is 
noteworthy that this protection is achieved with the drug administered at a clinically relevant 
time (namely, after the ischaemic insult and during reperfusion).  
 
Alternative explanations for the effectiveness of oxypurinol and deferoxamine should be 
considered. Xanthine oxidase inhibitors such as oxypurinol and deferoxamine may act by 
conserving purine nucleotide pools in ischaemic and reperfused tissue, thus providing a potential 
source of intracellular energy substrates. One may also speculate that these drugs have 
membrane stabilising effects. The lack of an assay directly to measure free radicals within tissues 
has forced investigators to make conclusions based on associations with suspected free radical 
events, rather than by directly measured cause and effect relations. 
 
The importance and extent of myocardial reperfusion injury in clinical practice are unknown. 
However, the increased use of coronary artery thrombolysis and coronary angioplasty suggests 
that this type of injury may become more common. The delayed and progressive nature of this 
injury indicates that there is an opportunity for therapeutic intervention in the acute 
postischaemic period. An effective treatment for reperfusion injury would have the potential to 
reduce the significant morbidity and mortality that occurs in the days and weeks that follow such 
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